November 9, 2017 / 9:55 PM / a month ago

Dynavax Hep B vaccine gets FDA approval

Nov 9 (Reuters) - Dynavax Technologies Corp’s twice-rejected hepatitis B vaccine was approved by the U.S. Food and Drug Administration on Thursday, marking the drug developer’s first regulatory approval.

The two-dose vaccine, Heplisav-B, is designed to enhance the body’s immune response to the hepatitis B virus in adults aged 18 years and older.

A panel of independent advisers to the FDA in July voted in favor of and recommended approving the vaccine. (Reporting by Divya Grover in Bengaluru; Editing by Savio D‘Souza)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below